Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Observational

Specimens for Lung Cancer Panel Design

NCT07401797 · tracked via the Priya Life Science USA tracker
Sponsor
Maverix Medical
Phase
Observational
Started
2024-08-07
Last updated
2026-02-10

Condition(s) studied

Lung Nodules

Study summary

This is an observational study designed to determine the optimal combination of biomarkers and clinical data for the early detection, confirmation, and better treatment of lung cancer including minimizing recurrence.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
6.1 Criteria for the no prior cancer suspicious nodule arm Inclusion: 1. The patient has at least one indeterminant nodule with a diameter greater than or equal to 5mm and a Mayo SPN risk greater than 5%, identified by radiology, that has not been biopsied or undergone surgery. 2. The patient and the treating physician intend to follow up on the nodule with a biopsy procedure, PET scan, or active surveillance, with the procedure or next surveillance planned within the next 7 months. 3. Ability to understand the study and sign an informed consent form 4. Relevant clinical data accessible 5. Ability and willingness to safely donate 40 mL of blood 6. Ability of the site to collect and process blood per protocol Exclusion 1\. The patient has one or more nodules with a Mayo SPN risk over 50% or a diameter of 30mm or greater. 2\. The patient has received surgical prep, including antibiotics, anesthesia, etc. Fasting is not exclusionary. 3\. Previous cancer diagnosis of any origin. 4. Is currently pregnant 5. Is currently a prisoner or becomes a prisoner at any point during the study 6. Is under age 18, is unable to consent, or requires a different person or entity to consent on their behalf 6.2 Criteria for the previous cancer suspicious nodule arm Inclusion: 1\. The patient has at least one indeterminant nodule with a diameter greater than or equal to 5mm and a Mayo SPN risk greater than 5%, identified by radiology, that has not been biopsied or undergone surgery. 2\. The patient and the treating physician intend to follow up on the nodule with a biopsy procedure, PET scan, or active surveillance, with the procedure or next surveillance planned within the next 7 months. 3\. The patient has been in remission for a previous cancer not of lung origin for more than 5 years. 4\. Ability to understand the study and sign an informed consent form 5. Relevant clinical data accessible 6. Ability and willingness to safely donate 40 mL of blood 7. Ability of the site to collect and process blood per protocol Exclusion 1. The patient has one or more nodules with a Mayo SPN risk over 50% or a diameter of 30mm or greater. 2. The patient has received surgical prep, including antibiotics, anesthesia, etc. Fasting is not exclusionary. 3. Previous cancer diagnosis in the lung (either of lung origin or metastasis to the lung). 4. The treating physician believes the lung nodule is a recurrence of a previously diagnosed cancer. 5. Is currently pregnant 6. Is currently a prisoner or becomes a prisoner at any point during the study 7. Is under age 18, is unable to consent, or requires a different person or entity to consent on their behalf 6.3 Criteria for the healthy volunteer arm Inclusion: 1. Ability to understand the study and sign an informed consent form 2. Relevant clinical data accessible 3. Ability and willingness to safely donate up to 40 mL of blood 4. The ability of the site to collect and process blood per protocol Exclusion 1\. Is currently pregnant 2. Is currently a prisoner or becomes a prisoner at any point during the study 3. Is under age 18, is unable to consent, or requires a different person or entity to consent on their behalf

Primary outcome measure(s)

  • Test performance — Two years from final case enrollment
    Analytical validity, clinical validity, and clinical utility. Ability to correctly re-risk indeterminate nodules and ability to change clinical care based on hypothetical treatment plans for different test outcomes. Actual test results will not be provided to physicians, and actual care will not be affected.

Trial sites (1)

FacilityCityRegionStatus
Maverix Medical Phoenix Arizona Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07401797 on ClinicalTrials.gov ↗ ← All trials in the USA